Amoy Diagnostics

Amoy Diagnostics

Amoy Diagnostics is a company that develops molecular diagnostics for oncology precision medicine

Amoy Diagnostics is a company that develops molecular diagnostics for oncology precision medicine. The company was founded in 2008, in Xiamen, Fujian, China.

The company primarily looks to provide a portfolio of molecular diagnostics kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits, which are all CFDA and CE certified. The company serves over 300 hospitals in China as well as 50 other countries around the world.

COVID-19

With the outbreak of COVID-19, the company looks to provide quick and accurate diagnosis of diseases, especially the coronavirus. The company has developed a PCR-based test kits and has entered the NMPA (China's National Medical Products Administration) emergency approval channel.

The company's PCR-based test kits are meant to produce detection products for gene mutations, amplifications, nucleic acid extraction reagents, and other relation products. Their kits work with cancer, but they look to use them with the help of identifying coronavirus.

Timeline

September 2013
Amoy Diagnostics raises a $4,400,000 series B round from QiMing Venture Partners.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Amoy Diagnostics, Series B, September 2013
4,400,000
September 2013
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Zheng Limou

President

Further reading

Title
Author
Link
Type
Date

As Worries Grow Over Novel Coronavirus, Dx Industry Jumps Into Action

Web

Coronavirus and the race to distribute reliable diagnostics

Web

February 19, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Amoy Diagnostics

Zheng Limou

Xiamen, Fujian, China

PCR-based test kits

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.